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INTRODUCTION 
Express sequence tags (ESTs) are “tiny portion[s] of an 
entire gene that can be used to help identify unknown genes 
and to map their positions within a genome.”1 In layman’s 
terms, an EST is simply a copy of one part of a gene.  Since 
proteins play crucial roles in diseases and genes code for 
proteins, using ESTs to identify genes is a powerful method of 
studying diseases.  A recent point of controversy surrounding 
ESTs is whether or not they should be patentable. 
In re Fisher2 addresses this very question.  In Fisher, the 
court addressed the standard of usefulness required for 
patentable inventions under 35 U.S.C. § 101 as applied to 
ESTs.  The Fisher court considered whether ESTs 
corresponding to genes of an unknown function are capable of 
satisfying the utility requirement.  The Fisher court ultimately 
found that the claimed ESTs lacked specific and substantial 
utility because they were “only tools to be used along the way 
in the search for a practical utility” and, therefore, lacked an 
“immediate, well-defined, real world benefit” requisite to a 
finding of “substantial” utility considered mandatory under 35 
U.S.C. § 101.3 
This Note first asks whether ESTs should be patentable 
and then analyzes the viability of the current utility 
requirement of the Patent Act4 as applied to ESTs.  The 
Background section gives an overview of the requirements for 
patentability, the evolution of judicial interpretations of the 
utility requirement for patentability, and the U.S. Patent and 
Trademark Office’s (USPTO) interpretation of the utility 
requirement as embodied in its revised Guidelines manual.5  
Next, this Note analyzes the reasoning in Fisher and 
addresses whether the Fisher decision and current 
patentability requirements are in line with the goals of the 
patent system.  This Note concludes that the current test for 
utility of ESTs fails because it is unviable in its application to 
research tools and inconsistent with the general goals of the 
 1. Nat’l Ctr. For Biotech. Info., Just the Facts: A Basic Introduction to 
the Science Underlying NCBI Resources, available at 
http://www.ncbi.nlm.nih.gov/About/primer/est.html (Revised Mar. 29, 2004). 
 2. In re Fisher, 421 F.3d 1365 (Fed. Cir. 2005). 
 3. Id. at 1376. 
 4. The Patent Act, 35 U.S.C. §§ 100-376 (2000). 
 5. Utility Examination Guidelines, 66 Fed. Reg. 1092 (Jan. 5, 2001). 
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patent system.  A new, bright-line test should be adopted in its 
place, which alters the substantiality prong of the test in its 
application to research tools.  Such a test would promote the 
goals of the patent system and encourage the “progress of 
science”6 by allowing more research tools to qualify for 
patents. 
 I. BACKGROUND 
A.  UTILITY REQUIRED BY THE CONSTITUTION 
The U.S. Constitution gives Congress the power to 
“promote the Progress of Science and useful Arts by 
securing . . . exclusive Right[s] to . . . Discoveries.” 7  This 
declaration expressly limits the congressional grant of patents 
to useful discoveries and is the basis for the statutory utility 
requirement for patents.8  Under 35 U.S.C. § 101, patents may 
be granted for inventions that involve patentable subject 
matter9 and are useful,10 non-obvious,11 novel,12 and 
adequately disclosed.13  Section 101 codifies the utility prong 
of the patentability requirements, stating, “[w]hoever invents 
or discovers any new or useful process, machine, manufacture, 
or composition of matter, or any new and useful improvement 
thereof, may obtain a patent . . . .”14 
B.  JUDICIAL INTERPRETATION OF UTILITY REQUIREMENT 
Courts first interpreted the statutory utility requirement 
in Lowell v. Lewis.15  In Lowell, Justice Story (while riding 
circuit) adopted a de minimus view of utility and a 
correspondingly low threshold for patentability, allowing 
patents for compounds with no specific utility as long as they 
 6. U.S. CONST. art. I, § 8, cl. 8. 
 7. Id. 
 8. See, e.g., Stiftung v. Renishaw PLC, 945 F.2d 1173, 1180 (Fed. Cir. 
1991). 
 9. The Patent Act, 35 U.S.C. § 101 (2000). 
 10. Id. 
 11. Id. § 103. 
 12. Id. § 102. 
 13. Id. § 112. 
 14. Id. § 101. 
 15. Lowell v. Lewis, 15 F. Cas. 1018 (D. Mass. 1817). 
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were “more or less usefu[l].”16  The Court of Customs and 
Patent Appeals (CCPA) later established the requirement of 
utility for chemical compounds, holding that a patent 
application must include an “assertion of utility and an 
indication of the use or uses intended.”17  This test was 
softened when the court subsequently held that if actual 
utility exists, the degree to which it exists is “unimportant.”18 
The modern utility standard was established in 1966 by 
the Supreme Court in Brenner v. Manson.19  In Brenner, the 
Court narrowed what it perceived to be an overly broad field 
for patentability and created a more rigorous test that 
required an applicant to disclose one specific and substantial 
utility that qualifies under the USPTO’s Utility Examination 
Guidelines.20  The Brenner test remains the standard applied 
by courts today in determining the utility of inventions.21 
The Brenner standard was adapted to its current form in 
In re Kirk22 and In re Joly,23 which were decided on the same 
day.  Kirk extended Brenner to apply not only to the process 
that yielded unpatentable product, but also to intermediates 
in the production of compounds with no known use.  The court 
additionally found that the specificity requirement is not met 
if an application vaguely asserts that a compound is useful for 
its “biological activity” where “one skilled in the art would 
know how to use the compounds . . . to take advantage of their 
presently-existing biological activity.”24  In Joly, the majority 
came to a similar conclusion as the Kirk court, holding that a 
claimed use for a chemical compound as an intermediate to 
make other compounds without regard for the usefulness of 
the downstream compounds was inadequate to establish 
 16. Lowell, 15 F. Cas. at 1019. 
 17. In re Brenner, 182 F.2d 216, 217 (C.C.P.A. 1950) (emphasis omitted). 
 18. In re Nelson, 280 F.2d 172, 179 (C.C.P.A. 1960). 
 19. Brenner v. Manson, 383 U.S. 519 (1966). 
 20. Brenner, 383 U.S. at 534-35. 
 21. See, e.g., Fujikawa v. Wattanasin, 93 F.3d 1559, 1563 (Fed. Cir. 
1996) (“[I]t is well established that a patent may not be granted to an 
invention unless substantial or practical utility for the invention has been 
discovered or disclosed.”); In re Kirk, 376 F.2d 936 (C.C.P.A. 1967) (finding 
that intermediate compounds that produce other compounds with no known 
use do not satisfy the utility requirement). 
 22. Kirk involved an application alleging compounds useful for biological 
activity that someone skilled in the art could discern.  Kirk, 376 F.2d at 936-
46. 
 23. In re Joly, 376 F.2d 906 (C.C.P.A. 1967). 
 24. Kirk, 376 F.2d at 941. 
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utility.25 
C.  USPTO’S INTERPRETATION OF THE UTILITY REQUIREMENT 
The USPTO has published utility guidelines and training 
materials that outline patentability requirements.26  These 
guidelines do not carry precedential weight, but they are 
regularly relied upon by the courts when analyzing 
patentability.27 
In 1995, the USPTO published the Utility Examination 
Guidelines.28  These Guidelines made it easier to patent ESTs 
because they required that an applicant assert only a utility 
that was “specific” and “credible,” eliminating the requirement 
that the utility also be “substantial.”  The USPTO clarified its 
stance on patents for ESTs in 1997, declaring that failure to 
specify the function of the underlying gene from which that 
EST was derived was not a bar to patentability because ESTs 
had utility apart from the full-length genomic DNA sequences 
from which they were derived.29 
The USPTO changed its mind in 1999 when it issued its 
Revised Interim Utility Guidelines, which were intended to 
restrict the issuance of gene patents in response to substantial 
criticism from the public and private sectors.30  The revised 
directives established a heightened standard for utility under 
the “credible utility” test, so that “credible utility” was not 
sufficient without an additional showing of “specific” and 
“substantial” utility.31 
 25. Joly, 376 F.2d at 908 (emphasis omitted). 
 26. See generally Utility Examination Guidelines, supra note 5 at 1092; 
U.S. PATENT & TRADEMARK OFFICE, MANUAL OF PATENT EXAMINING 
PROCEDURE  (8th ed. 2004). 
 27. The MANUAL OF PATENT EXAMINING PROCEDURE, supra note 26, and 
Utility Guidelines, supra note 5, are not binding on a court, but they may be 
given judicial notice to the extent that they do not conflict with patent 
statutes.  See, e.g., Enzo Biochem v. Gen-Probe Inc., 323 F.3d 956, 964 (Fed. 
Cir. 2002) (citing Molins PLC v. Textron, 48 F.3d 1172, 1180 n.10 (Fed. Cir. 
1995)). 
 28. See Utility Examination Guidelines, 60 Fed. Reg. 36,263, 36,264 
(July 14, 1995). 
 29. Posting of Donald Zuhn, In re Fisher: EST Patentability Redux, 
http://www.patentlyo.com/patent/2005/05/post.html (May 2, 2005). See 
generally Donald L. Zuhn, DNA Patentability: Shutting the Door to the Utility 
Requirement, 34 J. MARSHALL L. REV. 973 (2001). 
 30. See Revised Interim Utility Examination Guidelines; Request for 
Comments, 64 Fed. Reg. 71, 440 (Dec. 21, 1999). 
 31. Revised Utility Guidelines, 64 Fed. Reg. 71,440 (Dec. 21, 1999).  See 
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In 2001, the USPTO issued its current version of the 
Utility Examination Guidelines.  These Guidelines 
incorporated the same definitions of “specific,” “substantial” 
and “credible” that were used in the 1999 Guidelines, except 
that the 2001 Guidelines adopted a “specific, substantial, and 
credible” test that incorporated a “well-established utility” 
analysis that was previously a separate test for utility.32  
Therefore, if an invention lacks specific, substantial, and 
credible utility it fails under both tests.  An assertion is 
credible unless “the logic underlying the assertion is seriously 
flawed” or “the facts upon which the assertion is based are 
inconsistent with the logic underlying the assertion.”33  This is 
not a significant hurdle to satisfy the utility requirement.  The 
more substantial requirements are those which require that 
the utility be “specific,” which means that it is specific to the 
subject matter claimed in the application, and “substantial,” 
which means that it has a “real world” use.34 
Court precedent has favored a narrow interpretation of 
the utility requirement following the Supreme Court’s Brenner 
decision.35  This has been followed by the USPTO in its most 
recent Guidelines.36  Whether this is an appropriate 
interpretation, specifically with regard to express sequence 
tags, remains an open question. 
D.  WHAT ARE ESTS? 
In order to understand ESTs, it is important to have a 
basic understanding of genetics and how genetic research is 
used to study hereditary diseases.  The human body is made 
Stephen G. Kunin, Written Description Guidelines and Utility Guidelines, 82 
J. PAT. & TRADEMARK OFF. SOC’Y 77, 96-97 (2000) (concluding that the 
Revised Utility Guidelines address more specifically the issues of specific and 
substantial utility, while keeping the same standard for credible utility from 
the 1995 Guidelines). 
 32. The Fate of Gene Patents Under the New Utility Guidelines, 2001 
DUKE L. & TECH. REV. 8 (2001); see Utility Examination Guidelines, 66 Fed. 
Reg. 1092 (Jan, 5, 2001). 
 33. Id. See also UNITED STATES PATENT AND TRADEMARK OFFICE, 
REVISED INTERIM UTILITY GUIDELINES TRAINING MATERIALS 5 (1991) 
[hereinafter TRAINING MATERIALS]. 
 34. TRAINING MATERIALS at 5-6. 
 35. See In re Joly, 376 F.2d 906, 908 (C.C.P.A. 1967) (denying a patent 
application for an intermediate compound in the production of a steroid); see 
also In re Kirk, 376 F.2d at 936 (denying a patent application that contained 
vague claims asserting “biological activity” as the utility). 
 36. Utility Examination Guidelines 6, 66 Fed. Reg. 1092 (Jan. 5, 2001). 
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up of many different types of cells, each of which contains 
deoxyribonucleic acid (DNA), which guides the activities 
within that cell and determines the unique traits of that cell.  
DNA is composed of four distinct bases, which are the 
molecules adenine (A), guanine (G), cytosine (C), and thymine 
(T).  These bases form base pairs (A with T and G with C) that 
form a two-stranded DNA molecule.  Long sequences of 
double-stranded DNA comprise the total DNA of a cell, called 
its genome, which includes up to three billion bases in human 
cells.37  Genes are sequences of bases within a cell’s DNA38 
that give instructions to the cell on how to make proteins.39  
The different proteins encoded by genes are essential for the 
survival of an organism because they perform most functions 
necessary for life and make up most of the structures in a cell.  
Genes, in turn, are significant because they determine the 
chemistry and behavior of these proteins. 
When scientists are able to understand how a gene is 
expressed40 under normal circumstances (when a person is 
healthy), they can then study how it is expressed under 
abnormal circumstances (when a person has a disease).  In the 
past, this usually required scientists to identify a protein of 
interest, isolate that protein, determine its function, and then 
find the specific gene within the genome that coded for that 
protein.41  Alternatively, by starting research with the gene 
instead of the protein, scientists could determine the location 
of a given gene on the genome and then isolate the protein 
coded for by that gene.42  Both of these methods are time-
 37. Office of Biological & Envtl. Research, U.S. Dep’t of Energy Office of 
Sci., The Science Behind the Human Genome, 
http://www.ornl.gov/sci/techresources/Human_Genome/project/info.shtml 
(last modified Aug. 29, 2006). 
 38. Id. It is estimated that the human genome contains 20,000 to 25,000 
different genes. 
 39. Id. DNA sequences coding for genes comprise only 2% of the human 
genome.  The remainder consists of non-coding regions, which may provide 
instructions for regulating protein quantities or ensure structural integrity of 
chromosomes. 
 40. Wikipedia, Gene Expression, avaialable at 
http://en.wikipedia.org/wiki/Gene_expression (last visited Apr. 12, 2007). 
Gene expression is the process whereby a gene is “turned on” so that the 
expressed portions of a gene’s DNA sequence are “converted into the 
structures and functions of a cell.” In contrast, the non-protein encoding 
portions are not translated into protein. 
 41. Office of Biological & Envtl. Research, supra note 37. 
 42. Id. 
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consuming43 and costly, because they require expensive 
biochemical research methods and focus on only a single gene 
or protein at a time.44 
Express sequence tags can decrease the time and cost 
involved in genetic research.  According to the National 
Institutes of Health (NIH), express sequence tags are “unique 
segment[s] of cDNA with a base sequence[s] identical to at 
least part of the coding region of a gene, generally used as 
landmark for mapping.”45  In order to get a hold of these gene 
fragments, scientists must first separate the expressed 
sequences, which represent just 2% of the genome, from the 
non-expressed DNA in the genome, which represents the other 
98% of the cell’s DNA.46  This is a process that naturally 
occurs in the cell when messenger RNA (mRNA) is created 
along the pathway to protein formation.  Messenger RNA is an 
alternative form of DNA that represents only the expressed 
portion of DNA and is used by the cell to create proteins in a 
process called translation.47  Messenger RNA is not used 
extensively in genetic research because it is inherently 
unstable outside of a cell.48  Instead, scientists use enzymes to 
create cDNA from the mRNA that represents an exact replica 
of the cell’s original DNA, minus the unexpressed regions.49  It 
 43. In fact, these methods often take years.  Id. 
 44. EST sequences “can be generated rapidly and inexpensively, only one 
sequencing experiment is needed per each cDNA generated, and they do not 
have to be checked for sequencing errors because mistakes do not prevent 
identification of the gene from which the EST was derived.”  Nat’l Ctr. for 
Biotech. Info., supra note 1. 
 45. Nat’l Inst. on Alcohol Abuse and Alcoholism of the Nat’l Insts. of 
Health, Concepts and Terms in Genetic Research—A Primer, 
http://pubs.niaaa.nih.gov/publications/arh26-3/165-171.htm (Prepared June, 
2003). 
 46. Office of Biological & Envtl. Research, supra note 37. 
 47. Creating proteins from genes in DNA involves transcription, which is 
the creation of messenger RNA from DNA, followed by translation, which is 
the creation of a protein from the messenger RNA.  “During [transcription], 
mRNA passes through various phases, including one called splicing, where 
the non-coding sequences are eliminated. In the next step, translation, the 
mRNA guides the synthesis of the protein by adding amino acids, one by one, 
as dictated by the DNA and represented by the mRNA.”  Nat’l Ctr. for 
Biotech. Info., supra note 1. 
 48. Id. 
 49. Id.  According to the National Center for Biotechnology Information, 
cDNA is a “form of DNA prepared in the laboratory using an enzyme called 
reverse transcriptase. cDNA production is the reverse of the usual process of 
transcription in cells because the procedure uses mRNA as a template rather 
than DNA. Unlike genomic DNA, cDNA contains only expressed DNA 
sequences, or exons.”  Id. 
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is this cDNA that is used in the creation of ESTs. 
To create an EST, scientists isolate the cDNA that codes 
for a given protein and determine its sequence (the sequence 
of A, T, G, and C bases that make up the cDNA).50  Then they 
create a short sequence of bases, usually several hundred 
bases long, that complements either the beginning of the 
cDNA sequence (a 5’ EST tag) or the end of the cDNA 
sequence (a 3’ EST tag).51  A 5’ EST tags the portion of the 
cDNA that usually codes for a protein, while a 3’ EST tags the 
portion of the cDNA that is often part of an untranslated 
region.52  To study a genetic disease, scientists identify ESTs 
that may correspond to a gene involved in the disease, and 
then examine the DNA of disease-carrying patients for 
mutations in the gene to determine if they match.53  Other 
uses for ESTs include genome mapping, the process of creating 
an outline of identified genes in the human genome used by 
researchers to facilitate further research and understanding of 
the genome that often uses 3’ EST tags.54 
II. THE “SUBSTANTIAL” AND “SPECIFIC” UTILITY TEST 
A.  THE CURRENT UTILITY TEST UNDER BRENNER V. MANSON 
The current test for utility was created by the Supreme 
Court in 1966 in its decision in Brenner v. Manson.55  In 
Brenner the Court addressed whether the utility of a 
compound produced by a chemical process is an essential 
element of establishing a prima facie case for patentability of 
that process.56  The Court construed 35 U.S.C. § 101 narrowly 
in its application for method patents and held that utility is 
required for the product of a process as well as the process 
itself: 
 50. Id. 
 51. Id. 
 52. Id. 
 53. Nat’l Center for Biotech. Info., Just the Facts: A Basic Introduction to 
the Science Underlying NCBI Resources, ESTs: Gene Discovery Made Easier,  
http://www.ncbi.nlm.nih.gov/About/primer/est.html (Revised March 29, 
2004). This is the method used to determine the genes involved in 
Alzheimer’s disease and colon cancer, among others. 
 54. Id. 3’ EST tags are used for genome mapping because they are 
usually not conserved between species and thus represent unique identifiers. 
 55. Brenner, 383 U.S. at 519. 
 56. Id. at 520. 
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We find absolutely no warrant for the proposition that although 
Congress intended that no patent be granted on a chemical 
compound whose sole ‘utility’ consists of its potential role as an 
object of use-testing, a different set of rules was meant to apply to 
the process which yielded the unpatentable product.57 
The Brenner majority reasoned that the patentable field 
would be too broad with a standard that did not require utility 
for both the process and product.58  Consequently, the 
majority opined that the current de minimis utility standard59 
was out of line with the goals of the patent system because “a 
patent is not a hunting license . . . [or] a reward for the search, 
but compensation for its successful conclusion
The Brenner Court created a new test that put at its 
forefront the requirement that a patentable invention derive 
some benefit to the public that has “substantial utility” and a 
“specific benefit [that] exists in currently available form.”61  
Unfortunately the Supreme Court did not delineate what 
constitutes “specific” and “substantial” in determining 
whether an invention satisfies the utility requirement.  
Instead, the task of interpreting this test was left to appellate 
courts and the Court of Customs and Patent Appeals (CCPA) 
to determine in subsequent cases. 
B. “SUBSTANTIAL” UTILITY PRONG 
The Brenner test’s “substantial” utility requirement has 
been interpreted by the lower courts to require “practical 
utility” and “real world” utility.62  In Nelson v. Bowler, the 
court elucidated the requirement by explaining that, 
“‘[p]ractical utility’ is a shorthand way of attributing ‘real-
world’ value to claimed subject matter.  In other words, one 
skilled in the art can use a claimed discovery in a manner 
 57. Id. at 535. 
 58. The Brenner Court reasoned: “Until the process claim has been 
reduced to production of a product shown to be useful, the metes and bounds 
of that monopoly are not capable of precise delineation.  It may engross a 
vast, unknown, and perhaps unknowable area.”  Id. at 534. 
 59. The utility test used before Brenner v. Manson was that outlined in 
Lowell v. Lewis, where Justice Story held that 35 U.S.C. § 101 only requires 
that an invention not be frivolous or injurious to well-being, good policy, or 
the good morals of society. 15  F. Cas. 1018, 1019 (C.C.D. Mass. 1817) (No. 
8568). 
 60. Brenner, 383 U.S. at 536. 
 61. Id. at 534-35. 
 62. See In re Fisher, 421 F.3d 1365, 1376-77 (Fed.Cir. 2005). 
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which provides some immediate benefit to the public.”63  In 
addition to providing an immediate benefit to the public, the 
practical or real world utility must be in current form, 
showing a “significant and presently available benefit to the 
public.”64 
To assert utility for a method for making a corresponding 
product, such as a protein, under Brenner one must determine 
whether or not the corresponding product itself has 
substantial utility.65  According to the USPTO’s interpretation 
of Brenner as embodied in the Utility Guidelines, identifying 
and studying the properties of the corresponding product does 
not constitute a “real world” context of use.66  Therefore, the 
substantial utility test encompasses the requirement for a 
“real world” context of use that includes an immediate public 
benefit that is currently available as disclosed in the patent 
application. 
C. “SPECIFIC” UTILITY PRONG 
To satisfy the “specific” utility prong of the utility test, an 
application must “disclose a use which is not so vague as to be 
meaningless.”67  There must be a “well-defined and particular 
benefit to the public.”68  Vague assertions of “biological 
activity”69 or “biological properties”70 do not meet the 
standard.  In its non-binding Manual of Patent Examining 
Procedure (MPEP), the USPTO defined specific utility to 
require a use particular to the subject matter claimed in the 
application and not applicable to a broad class of inventions.71  
In contrast, general utility would apply to a broad class of an 
 63. Nelson v. Bowler, 626 F.2d 853, 856 (C.C.P.A. 1980). 
 64. Fisher, 421 F.3d at 1371. 
 65. See U.S. PAT. & TRADEMARK OFF., REVISED INTERIM UTILITY 
GUIDELINES TRAINING MATERIALS 50-53 (1999), available at 
http://www.uspto.gov/web/menu/utility.pdf. 
 66. Id. at 6.  According to the USPTO Utility Guidelines, “[u]tilities that 
require or constitute carrying out further research to identify or reasonably 
confirm a ‘real world’ context of use are not substantial utilities.”  Id. 
 67. Fisher, 421 F.2d at 1371. 
 68. Id. 
 69. In re Kirk, 376 F.2d 936, 941 (C.C.P.A. 1967). 
 70. Id. 
 71. U.S. PAT. & TRADEMARK OFF., MANUAL OF PATENT EXAMINING 
PROCEDURE § 2107.01 (8th ed., 5th rev. 2006), available at 
http://www.uspto.gov/web/offices/pac/mpep/mpep_e8r5_2100.pdf [hereinafter 
MPEP]. 
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invention.72  An example the USPTO gives to clarify this is 
directly applicable to ESTs: “a claim to a polynucleotide whose 
use is disclosed simply as a ‘gene probe’ or ‘chromosome 
marker’ would not be considered to be specific in the absence 
of a disclosure of a specific DNA target.”73  Further, the Utility 
Guidelines addresses the utility of hypothetical cDNA 
fragments used as probes for finding full-length genes and 
concludes that the utility lacks specificity because, 
[t]he use of the claimed nucleic acid is not particular to the sequence 
being claimed because it would be applicable to the general class of 
cDNAs.  Any partial nucleic acid prepared from any cDNA may be 
used as a probe in the preparation and or identification of a full-
length cDNA.74 
Therefore, to satisfy the specificity prong of the utility test 
an application must contain an asserted use that is specific 
enough that it cannot apply generally to an entire class of 
invention. 
III. THE FISHER DECISIONS 
A.  EX PARTE FISHER DECISION 
In Ex parte Fisher75 the U.S. Patent and Trademark 
Office Board of Patent Appeals and Interferences (BPAI) 
heard an appeal from an examiner’s rejection for lack of 
utility76 of a patent application claiming “[a] substantially 
purified nucleic acid molecule that encodes a maize protein or 
fragment thereof comprising a nucleic acid sequence” selected 
from a group of five claimed ESTs.77  The patent application 
asserted the following seven uses78 for the claimed ESTs: 
1. Serving as a molecular marker for mapping the entire 
 72. U.S. PAT. & TRADEMARK OFF., supra note 65, at 5. 
 73. Id. 
 74. Id. at 51. 
 75. 72 U.S.P.Q.2d 1020 (B.P.A.I. 2004). 
 76. Whether a patent application discloses the requisite utility for a 
claimed invention is a question of fact.  35 U.S.C. § 101 n.333.  A patent 
application that lacks utility also fails, as matter of law, for lack of 
enablement.  35 U.S.C. §§ 101 n.12, 112 n.4.  See also In re Brana, 51 F.3d 
1560, 1564 (Fed. Cir. 1995) (“Obviously, if a claimed invention does not have 
utility, the specification cannot enable one to use it.”). 
 77. The original application claimed 32,236 ESTs, but this was reduced 
to five claimed ESTs at the direction of the USPTO examiner, who upon 
examination for the merits entered a Restriction to reduce the claimed ESTs 
to five or fewer.  72 U.S.P.Q.2d at 1022. 
 78. In re Fisher, 421 F.3d 1365 (Fed. Cir. 2005). 
EWING L. In Re Fisher: Denial of Patents for ESTs Signals Deeper Problems in the Utility 
Prong for Patentability. MINN. J.L. SCI. & TECH. 2007;8(2):645-680. 
658 MINN. J. L. SCI. & TECH. [Vol. 8:2 
 
                                                          
 
maize genome, which consists of ten chromosomes that 
collectively encompass about 50,000 genes; 
2. Measuring the level of mRNA in a tissue sample via 
microarray technology to provide information about gene 
expression;79 
3. Providing source for primers for use in the polymerase 
chain reaction [PCR] process  to enable rapid and 
inexpensive duplication of specific genes;80 
4. Identifying the presence or absence of a polymorphism;81 
5. Isolating promoters82 via chromosome walking;83 
6. Controlling protein expression; and 
7. Locating genetic molecules of other plants and organisms. 
Although the Appellants asserted seven potential uses for 
ESTs, the application needed to disclose only a single specific 
and substantial utility in order to satisfy the utility 
requirement.84 
 79. Nat’l Center for Biotech. Info. supra note 1. Microarrays, also known 
as DNA on a chip, are, “a tool for analyzing gene expression that consists of a 
small membrane or glass slide containing samples of many genes arranged in 
a regular pattern.” Specifically, it works by using an mRNA molecule to 
hybridize with the DNA template from which it originated. This allows 
researchers to determine the expression levels of many genes at once by 
measuring the amount of mRNA bound to each site on the array. 
 80. PCR is a molecular biology technique used to replicate DNA 
exponentially.  PCR typically amplifies short pieces of DNA, up to ten kilo 
base pairs in length.  Wikipedia, Polymerase Chain Reaction, 
http://en.wikipedia.org/wiki/Polymerase_chain_reaction (last visited Apr. 18, 
2007). 
 81. In the field of biology, a polymorphism refers to having multiple 
alleles of a gene within a population, usually expressing different 
phenotypes.  Wikipedia, Polymorphism, 
http://en.wikipedia.org/wiki/Polymorphism (last visited Apr. 18, 2007). 
 82. “In genetics, a promoter is a DNA sequence that enables a gene to be 
transcribed. The promoter is recognized by RNA polymerase, which then 
initiates transcription. In RNA synthesis, promoters are a means to 
demarcate which genes should be used for messenger RNA creation - and, by 
extension, control which proteins the cell manufactures.”  Wikipedia, 
Promoter, http://en.wikipedia.org/wiki/Promoter (last visited Apr. 18, 2007). 
 83. Chromosome walking is a method in genetics for identifying and 
sequencing long parts of a DNA strand, e.g., a chromosome. As the 
traditional chain termination method does not allow long DNA strands to be 
sequenced, this method works by dividing the long sequence into several 
consecutive short ones . . . That way, the short part of the long DNA that is 
sequenced keeps ‘walking’ along the sequence. The method can be used to 
sequence entire chromosomes (thus, chromosome walking). Wikipedia, 
Chromosome Walking, http://en.wikipedia.org/wiki/Chromosome_walking 
(last visited Apr. 18, 2007). 
 84. Utility Examination Guidelines, 66 Fed. Reg. 1092, 1094 (2001). The 
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In analyzing the utility of the claimed ESTs, the BPAI 
focused primarily on three of the asserted uses: identifying a 
polymorphism, the use as a probe to isolate promoters, and the 
use as a source for primers.85  The court held that identifying 
a polymorphism, which claimants asserted was useful in 
identifying a common genetic heritage among populations, 
was indeed a use for the ESTs, but that the use failed to be 
substantial enough86 because it provided only the “barest 
information” about genetic heritage.87  With regards to the 
claimed use of ESTs as probes or primers, the court found that 
the ESTs were not “tissue specific, cell-specific, cell-type, 
developmental or environmentally regulated”88 because the 
cDNA library used to isolate the ESTs was not a subtractive 
cDNA library89 specific to portions of the genome actually 
expressed in leaf tissue during anthesis.90 In other words, the 
court found the claimed ESTs to be “randomly selected”91 so 
that there was no reasonable expectation that they could 
fulfill the claimed specific use in their currently available form 
Guidelines state that the patentee is “required to disclose only one utility, 
that is, teach others how to use the invention in at least one way. The 
patentee is not required to disclose all possible uses, but promoting the 
subsequent discovery of other uses is one of the benefits of the patent 
system.” 
 85. Ex parte Fisher, 72 U.S.P.Q.2d 1020, 1026 (2004). The BPAI 
combined the latter two uses, those of ESTs as probes and primers, under a 
single analysis.  In reviewing the court’s analysis, this Note also combines 
the two uses into a single analysis for the sake of clarity. 
 86. Id. The Ex parte Fisher court concluded that polymorphisms are 
natural variations that do not have an independent meaningful use and, 
therefore, a correct analysis would require first determining if there was a 
polymorphism and then determining “how to use this information in a 
patentably meaningful way.” 
 87. Id. 
 88. Id. at 1027. 
 89. A subtractive cDNA library is one which has effectively eliminated 
(“subtracted”) the cDNA from parts of the genome not of interest.  In the case 
of Fisher’s claimed ESTs, a subtractive cDNA library could subtract nucleic 
acid molecules from other, non-leaf maize tissue or from other developmental 
stages to leave only cDNA from maize leaf tissue from the anthesis 
developmental stage.  Id. 
 90. Id. Appellants argued that the claimed ESTs, which were isolated 
from maize leaves during anthesis, provided a useful starting point for 
isolating a promoter active in leaves during anthesis and that this 
constituted a substantial use because isolation of the promoter would allow 
research into protein expression during a developmental stage in the leaf life 
cycle, including proteins that provide disease resistance. 
 91. Id. 
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without being further “refined and developed.”92  Therefore, 
each use analyzed by the BPAI was rejected for failing the 
“substantial” use prong of the Brenner utility test. 
B. THE IN RE FISHER MAJORITY’S ANALYSIS: ESTS AS 
RESEARCH INTERMEDIATES 
In In re Fisher, the Federal Circuit heard the appeal of 
the BPAI decision finding that that the claimed uses for ESTs 
failed for lack of utility under the Brenner standard.93  The 
majority of the Federal Circuit found that the ESTs are “no 
more than research intermediates” that can be used to identify 
the underlying genes and conduct further research on those 
genes.94  The Federal Circuit held that ESTs, as research 
intermediates, fail the utility standard because there is “no 
assurance that anything useful will be discovered in the 
end.”95 
1. “Substantial” Use 
The court agreed with the Appellants that the seven 
asserted uses in the application were valid experimentation 
goals for ESTs, but found that there was no satisfactory 
evidence that the claimed ESTs could actually be used in the 
seven ways outlined in the patent application.96  The ESTs 
failed to satisfy the Brenner utility standard because they 
remained “object[s] of use-testing”97 without any current real-
world utility. 
Most of the claimed uses for ESTs involved studying other 
molecules.98  The majority advanced the BPAI’s utility inquiry 
by exploring not only whether the claimed uses satisfied the 
utility standard, but whether the products associated with the 
ESTs (i.e., the underlying gene corresponding to the EST, the 
protein expressed by the underlying gene, or the promoter 
that an EST could locate) satisfied the utility standard 
 92. Id. 
 93. In re Fisher, 421 F.3d 1365, 1369 (Fed. Cir. 2005). 
 94. Id. at 1373. 
 95. Id. 
 96. Id. at 1373–74.  The Court of Appeals found that there was no 
evidence showing that any polymorphisms, any promoters, or any genetic 
molecules in other plants or organisms had been identified, or that the ESTs 
had been used as molecular markers in maize genome mapping. 
 97. Id. at 1374; Brenner, 383 U.S. at 535. 
 98. See Fisher, 421 F.3d at 1376. 
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independently.99  Under Brenner, a useful process must yield 
a product that independently satisfies the utility test.100  
Therefore, if an EST is useful because it can identify an 
underlying gene, then that underlying gene must have a 
specific and substantial use itself.  Similarly, if an EST is 
useful because it can identify a promoter or polymorphism, 
then that promoter or polymorphism must also have a specific 
and substantial use.  The majority applied Brenner and found 
that products of processes or experiments identified as uses for 
ESTs must themselves have a use that satisfies the utility 
standard.101  For Fisher’s claimed ESTs, the court determined 
that the underlying genes, the corresponding promoters, and 
the associated polymorphisms failed to satisfy the utility 
standard.102  Therefore, the ESTs failed the utility test for 
lack of substantial u
2. “Specific” Use 
The Fisher majority found that the claimed ESTs also 
failed the “specific” use prong of the Brenner utility test.103  
The court determined that the asserted uses were general in 
nature rather than specific to the ESTs in the application (i.e., 
the exact nucleotide sequence of each EST identified) and 
therefore failed for lack of specificity.104  The court reasoned 
that: 
[A]ny EST transcribed from any gene in the maize genome may be a 
molecular marker or a source for primers.  Likewise, any EST 
transcribed from any gene in the maize genome may be used to 
measure the level of mRNA in a tissue sample, identify the presence 
or absence of a polymorphism, isolate promoters, control protein 
expression, or locate genetic molecules of other plants and 
organisms.105 
The court determined that nothing about the asserted 
uses for the five claimed ESTs made them distinct “from the 
more than 32,000 ESTs disclosed in the . . . application or 
 99. See id. at 1374. 
 100. See Brenner, 383 U.S. at 534. 
 101. See Fisher, 421 F.3d at 1373–76.  As an example, the court 
illustrated that an EST may be used to detect a complementary genetic 
sequence of DNA, but it is unable by itself “to provide any information about 
the overall structure let alone the function of the underlying gene.” Id. at 
1373. 
 102. Id. at 1373. 
 103. Id. at 1374. 
 104. Id. 
 105. Id. 
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indeed from any EST derived from any organism.”106  Fisher’s 
ESTs failed the specificity test because they were general, 
rather than specific, in nature and they could apply to “any 
EST transcribed from any gene in the maize genome.”107 
The court again extended the analysis to address the 
utility of the products associated with the claimed ESTs.  In 
analyzing the specific utility of the products correlated with 
the ESTs, the court relied heavily on In re Kirk.108  Kirk 
extended Brenner to apply not only to processes that yielded 
unpatentable product, but to intermediates in the production 
of compounds with no known use.109  Under Kirk, a compound 
that is useful as an intermediate step in the preparation of 
compounds of unknown use fails to have specific utility.110  “It 
is not enough that the specification discloses that the 
intermediate exists and that it ‘works,’ reacts, or can be used 
to produce some intended product of no known use.”111 
Therefore, under this expanded test the ESTs would remain 
subject to the Brenner test even if they did not constitute a 
“process” because they qualify as intermediates in the 
production of compounds with no known use.  Applying the 
test to the claimed ESTs as intermediate compounds, the court 
held that they lacked specificity because they disclosed 
products of unknown use (i.e., there was no known specific use 
for the underlying gene or protein it encoded).112 
C.  THE IN RE FISHER DISSENT’S ANALYSIS: ESTS AS RESEARCH 
TOOLS 
Judge Rader dissented from the Fisher majority, 
disagreeing with the identification of ESTs as research 
intermediates.113  Instead, he argued that ESTs constitute 
 106. Id. 
 107. Id. 
 108. 376 F.2d 936 (C.C.P.A. 1967).  See also In re Joly, 376 F.2d 906 
(C.C.P.A. 1967) (adopting the reasoning of the In re Kirk court to nearly 
identical facts); In re Fisher, 421 F.3d 1365, 1374–77 (Fed. Cir. 2005). 
 109. Kirk, 376 F.2d at 945–46. 
 110. Id. 
 111. Id. at 945.  The court went on to comment that it is not enough that 
“the product disclosed [is] obtained from [an] intermediate [that] belongs to 
some class of compounds which now is, or in the future might be, the subject 
of research to determine some specific use.”  Id. at 945 (footnote omitted). 
 112. Fisher, 421 F.3d at 1375–77. 
 113. See id. at 1379 (Rader, J., dissenting). 
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research tools, which have utility that is “generally . . . beyond 
question”114 in a utility analysis by the USPTO.  Judge Rader 
agreed with the majority that if the Brenner test applied to 
ESTs (i.e., if ESTs are methods rather than research tools) 
that the ESTs would fail to be patentable for lack of utility.115 
There is currently no bright line test to determine what 
constitutes a research tool.  The USPTO has not explicitly 
defined what constitutes a research tool, although it restricts 
what constitutes a research tool by preventing patents for 
tools that do not provide “substantial” advances.116  Janice 
Mueller, in an article about patent infringement for 
biomedical research tools, defined research tools as “the many 
varied resources used by scientists to conduct research and 
development of new drugs, therapies, diagnostic methods, and 
other therapeutic products.”117  Research tools may include 
biochemicals, such as reagents, plasmids, antibodies, and 
enzymes used to develop subsequent pharmaceutical end 
products or they may include a device that can be used and 
reused during the course of research, such as PCR.118  The 
NIH defines research tools as “the full range of tools that 
scientists use in the laboratory, including cell lines, 
monoclonal antibodies, reagents, animal models, growth 
factors, combinatorial chemistry and DNA libraries, clones 
and cloning tools (such as PCR), methods, laboratory 
equipment and machines.”119 
The dissent in Fisher adopted this same broad definition 
of research tools.  Opining that ESTs constitute research tools, 
Judge Rader argued that although the ESTs in the application 
corresponded to genes of unknown function, the ESTs 
nonetheless remain research tools because they “enhance 
research” into “isolating and studying other molecules”120  by 
taking a researcher “one step closer to identifying and 
 114. Id. 
 115. Id. 
 116. See MPEP, supra note 71, § 2107.01. 
 117. Janice M. Mueller, No “Dilettante Affair”: Rethinking the 
Experimental Use Exception to Patent Infringement for Biomedical Research 
Tools, 76 WASH. L. REV. 1, 4 (2001). 
 118. Natalie M. Derzko, In Search of a Compromised Solution to the 
Problem Arising from Patenting Biomedical Research Tools, 20 SANTA CLARA 
COMPUTER & HIGH TECH. L.J. 347, 348 (2004). 
 119. Principles and Guidelines for Recipients of NIH Research Grants and 
Contracts on Obtaining and Disseminating Biomedical Research Resources: 
Final Notice, 64 Fed. Reg. 72,090, 72,092 n.1 (Dec. 23, 1999). 
 120. Fisher, 421 F.3d at 1379 (Rader, J., dissenting). 
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understanding a previously unknown and invisible 
structure.”121  Rader’s dissent concluded that ESTs qualify as 
research tools which have established utility in a laboratory 
research setting, and that the strict Brenner utility test was 
therefore inapplicable.122 
IV. IMPLICATIONS OF IN RE FISHER: A BETTER 
UTILITY TEST IS NEEDED 
A.  THE BRENNER TEST IS ILL-SUITED FOR DETERMINING 
UTILITY 
The Brenner utility test fails to meet the needs of modern 
scientific research.  There are practical problems with the 
application of a rule that lacks bright-line standards123 for 
satisfying its individual prongs and policy problems associated 
with a rule that was created during a time before the advent 
of modern molecular genomics.  The greatest problem with the 
test is not the specificity prong, which rightly requires an 
invention to have a specific, rather than general, application; 
it is the vague and poorly applied substantial utility prong, 
which lacks relevance in contemporary scientific research. 
In the wake of Brenner, courts have interpreted 
“substantial” as requiring “one skilled in the art” to be able to 
use the discovery, in its currently available form, in a manner 
providing an “immediate benefit to the public.”124  If the 
Fisher court’s interpretation of this rule is correct, in that an 
invention has utility only if the studied object is 
understandable using the claimed invention, then “only the 
final step of a lengthy incremental research inquiry gets 
protection.”125  This standard is unrealistic for research-
related inventions, which by their very nature encompass 
 121. Id. at 1380 (Rader, J., dissenting). 
 122. See id. at 1379–82 (Rader, J., dissenting). 
 123. The practical problems associated with the Brenner rule were 
predicted by Judge Rich, dissenting in Kirk: 
But then we come to the practical problem posed by the rule being 
promulgated by the majority—a rule of great vagueness and no 
definite limits by reason of reliance on the terms “practical,” 
“substantial,” “specific,” and “currently available.” They are nothing 
but trouble-makers, as time will amply demonstrate. 
376 F.2d 936, 960 (C.C.P.A. 1967) (Rich, J., dissenting). 
 124. Nelson v. Bowler, 626 F.2d 853, 856 (C.C.P.A. 1980). 
 125. Fisher, 421 F.3d at 1380 (Rader, J. dissenting). 
EWING L. In Re Fisher: Denial of Patents for ESTs Signals Deeper Problems in the Utility 
Prong for Patentability. MINN. J.L. SCI. & TECH. 2007;8(2):645-680. 
2007] IN RE FISHER: DENIAL OF PATENTS FOR ESTS 665 
                                                          
research into the unknown.  For research-related inventions, 
the public benefits from the research as it is conducted 
because each incremental step brings a scientist closer to an 
ultimately large discovery.  This does not mean that the 
incremental step is insignificant or lacking a benefit to society.  
To the contrary, “[e]ach step, even if small in isolation, is 
nonetheless a benefit to society sufficient to give a viable 
research tool ‘utility’ under § 101 . . . [because even] 
experiments that fail still serve to eliminate some possibilities 
and provide information to the research process.”126  Under 
the current reasoning, the requirement of an immediate public 
benefit would have precluded many important past inventions 
simply because the public benefit was not in currently 
available form.127 
The current substantial utility prong requires an inquiry 
into whether or not a product corresponding to the claimed 
invention itself has substantial utility.128  In creating this 
requirement, the Brenner Court reasoned that without this 
virtual fence in place, the monopoly created by a patent would 
have no identifiable boundaries, that it could be “vast” and 
unknowable.129  This argument lacks validity because process 
claims are not denied based on whether or not what they 
produce may ultimately cause a monopoly that is greater than 
expected, since “a hundred more uses may be found after a 
 126. Id. at 1381 (Rader, J., dissenting). 
 127. This was noted by Justice Rich, who dissented to the majority’s 
denial of a patent for lack of utility in In re Joly: 
It is fortunate indeed that such a view did not prevail in the past. 
Under such a test I seriously doubt whether the present majority 
would find the first powered flight of the Wright Brothers to be 
“useful.” Since it lasted but 12 seconds, traversed but 120 feet, and 
reached a maximum height of but 10 feet, it cannot be said to have 
had a “practical” or “substantial” utility or that it made powered 
flight practical or substantial in a then “currently available form.” 
Under the majority view such a flight would indeed be “useless.” 
376 F.2d 906, 917 (C.C.P.A. 1967). 
 128. U.S. PAT. & TRADEMARK OFF., supra note 65, at 50–53 (1999), 
available at www.uspto.gov/web/menu/utility.pdf. 
 129. Brenner, 383 U.S. at 534. 
Until the process claim has been reduced to production of a product 
shown to be useful, the metes and bounds of that monopoly are not 
capable of precise delineation.  It may engross a vast, unknown, and 
perhaps unknowable area.  Such a patent may confer power to block 
off whole areas of scientific development, without compensating 
benefit to the public. 
Id. at 534 (footnote omitted). 
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patent is granted and greatly enhance its value.”130  The 
Brenner court also justified this requirement by describing a 
useful product as the “basic quid pro quo”131 for a patent, a 
reward for the “successful conclusion” of the search for an 
invention.132  This argument; however, “beg[s] the very 
question whether the process is ‘useful’ simply because it 
facilitates further research into possible product uses.”133 
The current utility prong qualifies what constitutes 
substantial utility as only that which has a “real world” 
context, which does not include identifying and studying the 
properties of a product corresponding to an invention.134  The 
reasoning behind this requirement, created by Brenner and 
reinforced by Kirk, is that “a method of producing a compound 
with no known use has no more benefit to society than the 
useless compound itself.”135  This is not always true in 
contemporary scientific research.  A research method that 
involves identifying and studying properties of products 
corresponding to an invention, such as studying the 
underlying gene and encoded protein associated with an EST, 
has a “real world” context: increasing the overall 
understanding of that product (i.e., increasing the overall 
understanding of the maize genome via research into the 
underlying gene and its unknown gene products).  Although 
this may not have been foreseeable at the time of Brenner, in 
contemporary science a “real world” context is present even 
with a conceivably small increase in understanding because of 
the fast-paced and interdisciplinary nature of research. 
Another problem with the substantial use prong of the 
utility test is that it is vague and open to subjective bias.  This 
was elucidated in Ex parte Fisher, where the court noted that, 
[s]omewhere between having no knowledge (the presence 
circumstances) and having complete knowledge of the gene and its 
role in the plant’s development and/or phenotype lies the line 
between “utility” and “substantial utility.” We need not draw the line 
 130. Id. at 537 (Harlan, J., concurring in part and dissenting in part). 
 131. Id. at 534. 
 132. Id. at 536. 
 133. Id. at 537 (Harlan, J., concurring in part and dissenting in part). 
 134. U.S. PAT. & TRADEMARK OFF., supra note 65, at 50–53.  According to 
the USPTO Utility Guidelines, “[u]tilities [that] require or constitute 
carrying out further research to identify or reasonably confirm a ‘real world’ 
context of use” are not substantial utilities.  Id. at 52–53. 
 135. In re Fisher, 421 F.3d 1365, 1380 (Fed. Cir. 2005) (Rader, J., 
dissenting). 
EWING L. In Re Fisher: Denial of Patents for ESTs Signals Deeper Problems in the Utility 
Prong for Patentability. MINN. J.L. SCI. & TECH. 2007;8(2):645-680. 
2007] IN RE FISHER: DENIAL OF PATENTS FOR ESTS 667 
                                                          
or further define it in this case because the facts in this case 
represent the lowest end of the spectrum, i.e., an insubstantial 
use.136 
There is no bright-line test for courts to use in 
interpreting exactly where on the spectrum a given invention 
may lie.  A test needs to be created because there is the 
temptation for courts to not elucidate their reasoning in 
determining where on the spectrum a given invention may 
reside.  For example, in Ex parte Fisher the court concluded 
that Fisher’s invention was on the lowest end of the spectrum, 
but failed to clarify why this was so.  A clarified substantiality 
test would preclude the temptation for courts to make 
conclusions without illuminating their reasoning while also 
promoting consistency in judicial decision-making. 
B.  AN APPROPRIATE UTILITY TEST COINCIDES WITH 
CONSTITUTIONAL REQUIREMENTS, CONGRESSIONAL INTENT, 
AND GOALS OF THE PATENT SYSTEM 
The Constitution grants Congress the power to “promote 
the Progress of Science and useful Arts by securing . . . 
exclusive Right[s] to . . . Discoveries.”137  Any law, judicial 
decision, or USPTO guideline must satisfy this constitutional 
requirement.  With the advent of modern science, just what 
constitutes progress has been difficult to determine and 
controversial.  As the dissenting Judge noted in Brenner, 
[t]o encourage one chemist or research facility to invent and 
disseminate new processes and products may be vital to progress, 
although the product or process be without “utility” . . . because that 
discovery permits someone else to take a further but perhaps less 
difficult step leading to a commercially useful item.138 
Determining what constitutes “Progress of Science” was 
difficult when the founding fathers created the Intellectual 
Property Clause139 and remains open to interpretation 
today,140 so that it is of little help in formulating a valid utility 
 136. Ex parte Fisher, 72 U.S.P.Q. 2d 1020, 1026 (Bd. Pat. App. Int. 2004). 
 137. U.S. CONST. art. I, § 8, cl. 8. 
 138. Brenner v. Manson, 383 U.S. 519, 539 (1966) (Harlan, J., concurring 
in part and dissenting in part). 
 139. U.S. CONST. art. I, § 8, cl. 8. 
 140. Thomas Jefferson wrote: “Considering the exclusive right to 
invention as given not of natural right, but for the benefit of society, I 
know well the difficulty of drawing a line between the things which are 
worth to the public the embarrassment of an exclusive patent, and those 
which are not.”  Letter from Thomas Jefferson to Isaac McPherson (Aug. 
13, 1813), in 13 THE WRITINGS OF THOMAS JEFFERSON 333–35 (Andrew 
A. Lipscomb & Albert Ellery Bergh eds., 1905), available at  
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test. 
Statutory language and congressional intent provide more 
guidance in creating an appropriate utility test for 
patentability.  The utility standard for patentability originated 
with the Patent Act of 1790, which used the term “useful.”141 
The Brenner court noted the problem with the vagueness of 
this term: 
Even if we knew precisely what Congress meant in 1790 when it 
devised the “new and useful” phraseology and in subsequent re-
enactments of the test, we should have difficulty in applying it in the 
context of contemporary chemistry where research is as 
comprehensive as man’s grasp and where little or nothing is wholly 
beyond the pale of “utility”—if that word is given its broadest 
reach.142 
The congressional intent behind the current statute143 is 
clearer because it was based in part on the Supreme Court 
decision in Diamond v. Chakrabarty,144 which codified the 
Court decision so that patentable subject matter includes 
“anything under the sun that is made by man.”145  Clearly this 
tends towards a view of the patent system favoring the 
granting of patents to inventors for a broad range of 
inventions. 
A proper utility test must adhere to constitutional and 
statutory requirements, but it should also promote the general 
goals of the patent system.  These goals are to reward an 
inventor for his contribution to society and to increase the 
public good with inventions.  U.S. Supreme Court Justice 
Stephen Breyer correctly concluded that patent law should 
encourage useful discovery and disclosure without unduly restricting 
the dissemination of those discoveries, hindering the circulation of 
important scientific ideas, or scattering ownership to the point 
where it inhibits the use of the underlying genetic advance.146 
The difficulty arises in balancing the interests of the 
public against those of the inventor.  The theory behind 
patents for inventions is that inventions promote the public 
http://press-pubs.uchicago.edu/founders/documents/a1_8_8s12.html. 
 141. Patent Act of 1790, ch. 7, 1 Stat. 109–12 (Apr. 10, 1790). 
 142. Brenner, 383 U.S. at 530. 
 143. 35 U.S.C. § 101 (2000). 
 144. 447 U.S. 303 (1980). 
 145. S. Rep. No. 82-1979 (1952); U.S. Code Cong. & Admin. News at 2394, 
2399. 
 146. Stephen G. Breyer, Genetic Advances and Legal Institutions, 28 J.L. 
MED. & ETHICS 23, 27 (2000). 
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good by enhancing the quality of life (e.g., with medicines to 
combat disease, machines to perform labor) and that 
inventors, because of their contribution to the public good, 
deserve to be rewarded for their contribution to society with a 
patent that confers a monopoly on that invention for a limited 
time.147  The patent encourages innovation (and therefore 
increases the public good) by rewarding the inventor for his 
toil.  When the monopoly conferred to the inventor is too 
broad, it limits the public good (e.g., by increasing the cost to 
the public of using the invention or preventing other inventors 
from using the invention as a means to create newer, better 
inventions).  The fear is that “[s]uch a patent may confer 
power to block off whole areas of scientific development, 
without compensating benefit to the public.”148  
Correspondingly, if a patent is too narrow or not allowed at 
all, a researcher may be discouraged from conducting 
research. 
V.  A REVISED UTILITY TEST 
A.  THE PROPOSED REVISION TO THE UTILITY TEST: AN 
ALTERED “SUBSTANTIAL” USE PRONG FOR RESEARCH TOOLS 
1.  Is it a Research Tool? 
The current utility test for patentability should be revised 
in its application to research tools.  In a revised utility test for 
research tools, the first consideration should be whether a 
given invention qualifies as a research tool.  As mentioned 
previously, there are presently no guidelines to determine 
whether or not a given invention qualifies as a research tool.  
This is because such a distinction is irrelevant with the 
current utility test.  The Fisher dissent loosely defines 
research tools as inventions that “enhance research,” but this 
is too broad and would provide little guidance.149  A better 
definition would use factors similar to those outlined by the 
 147. Patents “encourage dissemination of information concerning 
discoveries and inventions.” Brenner, 383 U.S. at 533 (citing Universal Oil 
Prods. Co. v. Globe Oil & Ref. Co., 322 U.S. 471, 484 (“As a reward for 
inventions and to encourage their disclosure, the United States offers a 
seventeen-year monopoly to an inventor who refrains from keeping his 
invention a trade secret.”)). 
 148. Brenner, 383 U.S. at 534. 
 149. Fisher, 421 F.3d at 1379 (Rader, J., dissenting). 
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NIH in considering whether a resource fits the definition of a 
research tool: 
1. The primary usefulness of the resource has as a tool for 
discovery rather than an FDA-approved product or integral 
component of such a product; 
2. Whether the resource is a broad, enabling invention that 
will be useful to many scientists . . . rather than a project or 
product-specific resource; and 
3. Whether the resource is readily useable or distributable as 
a tool rather than the situation where private sector 
involvement is necessary or the most expedient means for 
developing or distributing the resource.150 
These factors provide a good starting point for 
determining whether an invention is a research tool, but they 
need not be exhaustive.  It is, however, important that any 
definition adopted for research tools be able to readily 
distinguish between inventions, and aid in consistent judicial 
determinations. 
Determining whether or not an invention is a research 
tool does not conclude the revised utility test.  The property of 
being a research tool is not a utility in and of itself.  The 
USPTO warns that “[a]n assessment that focuses on whether 
an invention is useful only in a research setting thus does not 
address whether the invention is in fact ‘useful’ in a patent 
sense.”151  The invention must still have specific and 
substantial use, but what constitutes substantial use should 
be different for an invention that is a research tool. 
2.  Is the Use Substantial? 
The substantiality prong should be altered for inquiries 
regarding research tools.  A research tool should satisfy the 
substantiality prong even if it does not provide a traditionally 
recognized “immediate benefit to the public”152 in its currently 
available form.  This relaxed standard would recognize that 
“[s]cience always advances in small incremental steps”153 and 
that the public may benefit from each incremental step.  
Further, it should be irrelevant for research tools whether the 
product corresponding to the research tool itself has 
 150. NIH Principles and Guidelines, 64 Fed. Reg. 72,090, 72,094 (Dec. 23, 
1999). 
 151. MPEP, supra note 71, § 2107.01. 
 152. Nelson v. Bowler, 626 F.2d 853, 856 (C.C.P.A. 1980). 
 153. Fisher, 421 F.3d at 1380. 
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substantial utility.  Only the research tool itself should have 
required utility.  This recognizes that while the research 
process typically involves many unfruitful products before a 
fruitful product, this nonetheless does not negate the value of 
the process itself because “experiments that fail still serve to 
eliminate some possibilities and provide information to the 
research process.”154  A “real world” context of use that 
excludes “[b]asic research such as studying the properties of 
the claimed product itself or the mechanism in which the 
material is involved”155 should not be expressly excluded from 
potential patentability.  Instead, basic research using research 
tools that are themselves the subject of the research should be 
patentable if they have a “real world” use in a research or 
laboratory setting. 
3.  Is the Use Specific? 
The revised utility test for research tools should remain 
the same with regards to the test for specificity and would 
require a specific, as opposed to general, assertion of utility.  
This specific utility can be hypothetical, but it cannot be so 
hypothetical so as to be general.  A specific use does not 
necessarily negate a hypothetical use, especially with regards 
to research tools where a use may be known to exist (and 
therefore not general in nature) but may not actually have 
been carried out fully (and thus still technically hypothetical). 
B.  APPLICATION OF REVISED UTILITY TEST TO ESTS 
Under the revised utility test, Fisher’s claimed ESTs 
qualify as research tools.  Applying the NIH factors, Fisher’s 
ESTs are “tool[s] for discovery” that are useful in gaining 
understanding about the maize genome and the proteins 
encoded by the genes within that genome.  The specific ESTs 
claimed are product-specific resources because they apply to 
specific underlying genes within the maize genome.  ESTs, as 
a group, constitute a “broad, enabling invention that will be 
useful to many scientists” because ESTs can be used in many 
research contexts to better understand the genome of any 
species of interest.  Further, ESTs are “readily usable” as a 
tool because they can be created and used in any research 
setting or, alternatively, distributed to (or created by) any 
 154. Id. at 1381. 
 155. U.S. PAT. & TRADEMARK OFF., supra note 65, at 6. 
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laboratory that wishes to make use of them. 
Because ESTs would qualify as research tools, they would 
be subject to the revised substantiality prong for utility.  This 
means that the products associated with ESTs, such as the 
proteins encoded by the underlying gene or the underlying 
gene itself, need not independently exhibit substantial use.  
Only the ESTs themselves must exhibit “real world” use.  As a 
research tool usable in a laboratory setting for basic research 
studying the genes and encoded proteins of the maize genome, 
ESTs satisfy this standard. 
The claimed ESTs satisfy the relaxed substantial use 
prong for utility, but they must still exhibit specificity of use in 
order to have patentable utility.  Under the revised 
substantiality prong, “merely hypothetical”156 assertions of 
utility that represent what researchers may be able to do, 
rather than what they have already proven, are sufficient as 
long as they have a research context and correspond to a 
specific use.  Fisher’s ESTs have claimed uses that are 
applicable to all ESTs as a group and are therefore general in 
nature, rather than specific.  The claimed uses, including as a 
molecular marker or source for primers, apply to all ESTs 
associated with the maize genome.  Because of the extent of 
generality of the claimed uses, they could actually apply to 
any EST on any genome, not just the maize genome.  The 
generality of the claimed utilities results in Fisher’s ESTs 
failing the specificity prong of the revised utility test.  For this 
reason, the claimed ESTs fail to exhibit the requisite utility 
for patentability. 
Fisher’s claimed ESTs fail the revised utility test, but not 
all ESTs would necessarily fail the test.  ESTs could 
potentially pass a revised utility test if the claimed utility was 
specific to particular cDNA sequences being claimed, rather 
than applicable to a general class of cDNAs.157  An example of 
a specific use would be using an EST to control the protein 
expression of a specific protein A, rather than a general 
assertion of controlling protein expression of an unknown 
protein.  Another example of a sufficiently specific use would 
be using an EST corresponding to an underlying gene X to 
locate the Y gene in either plant A or organism B, as opposed 
to a general assertion of locating genetic molecules of other 
 156. Fisher, 421 F.3d at 1373. 
 157. U.S. PAT. & TRADEMARK OFF., supra note 65, at 51. 
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plants and organisms. 
C.  APPLICATION OF REVISED UTILITY TEST TO OTHER 
POTENTIAL RESEARCH TOOLS 
1.  Partially Characterized Proteins 
Under the USPTO’s current Guidelines, which are based 
on the Brenner utility test, partially characterized proteins are 
generally unpatentable.158  The revised Guidelines give an 
example of a protein with a disclosed amino acid sequence and 
a non-explicitly disclosed utility demonstrating that the 
protein can “specifically bind with another protein X such that 
X can be isolated and quantified.”159  The asserted utility 
qualifies as specific because it indicates that the claimed 
protein will specifically bind to protein X.160  However, under 
the current utility test, the asserted utility lacks substantial 
utility because there is no disclosed “real world” use since 
further experimentation is needed to elucidate a use for the 
claimed protein.161 
Under the revised utility test, such a partially 
characterized protein would qualify as a research tool because 
it is a “tool for discovery” that could be used, for example, to 
learn the role of the claimed protein and protein X in the 
context of a cell and to investigate their potential downstream 
therapeutic uses.  Knowledge of such protein-protein 
interactions would constitute a “broad, enabling invention . . . . 
useful to many scientists” and would be readily usable and 
distributable.162  As a research tool, the claimed protein would 
be subject to the relaxed substantial utility prong, which 
would not require an immediate benefit to the public in 
currently available form.163  Using the partially characterized 
protein in a research setting to better understand biological 
processes would constitute a sufficient real world use to satisfy 
utility.  Therefore, unlike the current Brenner standard, the 
proposed revised utility test would render partially 
characterized proteins patentable as research tools. 
 158. Utility Examination Guidelines, 66 Fed. Reg. 1092 (Jan. 5, 2001). 
 159. Id. at 34. 
 160. Id. at 35. 
 161. Id. 
 162. NIH Principles and Guidelines, 64 Fed. Reg. at 72,094. 
 163. Nelson, 626 F.2d at 856. 
EWING L. In Re Fisher: Denial of Patents for ESTs Signals Deeper Problems in the Utility 
Prong for Patentability. MINN. J.L. SCI. & TECH. 2007;8(2):645-680. 
674 MINN. J. L. SCI. & TECH. [Vol. 8:2 
 
                                                          
 
2.  Receptor Molecules 
Similarly, under the current utility test, receptor 
molecules are typically unpatentable for lack of utility.  One 
example illustrating this, given by the USPTO in its revised 
Guidelines, is that of a claimed protein receptor A, which 
binds to protein X of unknown identity, but has not been 
characterized with regards to its biological function or role in 
any disease or condition.164  The asserted utility is for 
“identifying materials that bind the receptor and the potential 
use of such materials as therapeutics” and for producing a 
monoclonal antibody that binds receptor A.165 
The hypothetical receptor A has sufficient specificity 
under the Brenner utility test because the claimed uses, 
identifying materials that bind only receptor A and making 
antibodies that bind only receptor A, are not applicable to a 
general class of receptor molecules.166 
In determining whether the substantial utility prong is 
satisfied, the current utility test requires not only that 
receptor A have substantial utility, but additionally that the 
materials that bind receptor A and the antibody that binds 
receptor A have substantial utility apart from that of receptor 
A itself.167  The method of identifying materials that bind 
receptor A has an asserted therapeutic use to “effect control 
over receptor A” that fails for lack of substantial utility since 
“a method of treating an unspecified, undisclosed disease or 
condition, does not define a ‘real world’ context of use.”168  The 
disclosed method of making an antibody for receptor A also 
fails for lack of substantial utility for the same reason.169  
Since both the material that binds receptor A and the antibody 
for receptor A lack substantial utility, receptor A fails the 
Brenner utility test. 
Under the proposed revised utility test, receptor A would 
likely qualify as a research tool because it is a “tool for 
discovery” to be used in researching diseases or conditions 
related to the activity of the receptor, because it is a “broad, 
enabling invention” useful to any scientist researching the role 
 164. U.S. PAT. & TRADEMARK OFF., supra note 65, at 63. 
 165. Id. 
 166. Id. at 65. 
 167. Id; see Brenner, 383 U.S. at 535-36. 
 168. U.S. PAT. & TRADEMARK OFF., supra note 65, at 65. 
 169. Id. 
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of receptors generally or the specific role of receptor A in 
various cellular processes, and because it is “readily useable or 
distributable as a tool” by any researcher who could isolate the 
protein in her laboratory from cellular extracts.  As a research 
tool, the receptor would be subject to the relaxed substantial 
utility prong. 
Under the revised utility test, receptor A would be 
considered useful because it aids in the incremental discovery 
process of understanding a disease mechanism, which would 
constitute a substantial utility in that it serves to “eliminate 
some possibilities and provide information to the research 
process.”170  Importantly, under the revised utility test it 
would be unnecessary to separately determine the utility of 
either the material that binds receptor A or the antibody for 
receptor A since “studying the properties of the claimed 
product itself or the mechanism in which the material is 
involved”171 would not be expressly excluded as a substantial 
utility.  Therefore, under a revised utility test, a receptor 
molecule such as receptor A would not be denied patentability 
as it would under the Brenner standard for lack of substantial 
utility. 
3.  Large Chemical Groups 
Large chemical groups are generally unpatentable for lack 
of substantial use under the current utility test.  An example 
given by the USPTO in its revised Guidelines is that of a 
claimed group of chemical compounds sharing a chemical 
formula.172  The hypothetical chemical compounds have no 
asserted physical, chemical, or biological properties, and an 
asserted use as biomedical research tools after the physical, 
chemical, and biological properties are determined.173  Under 
the current utility test, there is no specific utility because all 
chemical compounds can potentially be used for biomedical 
research, so that the utility is general in nature.174  The 
hypothetical chemical group also lacks substantial utility 
because biomedical research to determine the properties of the 
compounds does not constitute a “real world” context of use, 
since further research would be required to find a downstream 
 170. Fisher, 421 F.3d at 1381 (Rader, J., dissenting). 
 171. U.S. PAT. & TRADEMARK OFF., supra note 65, at 6. 
 172. Id. at 71–74. 
 173. Id. 
 174. Id. 
EWING L. In Re Fisher: Denial of Patents for ESTs Signals Deeper Problems in the Utility 
Prong for Patentability. MINN. J.L. SCI. & TECH. 2007;8(2):645-680. 
676 MINN. J. L. SCI. & TECH. [Vol. 8:2 
 
                                                          
 
application for the compounds once their properties were 
discovered.175 
Under the proposed revised utility standard, the chemical 
group would constitute a research tool because the primary 
use would be as a “tool for discovery” in biomedical research, 
which would be broad and enabling since it is a large chemical 
group with many potential avenues for biomedical research, 
and readily useable by a scientific laboratory in any way they 
saw fit for their given avenues of research using the claimed 
compounds.176  As a research tool, the chemical group would 
be subject to the revised substantial utility prong.  It would 
satisfy the substantial utility requirement since a “real world” 
context would include utility as a tool in biomedical research. 
However, the hypothetical chemical group would still fail 
to be patentable under the revised test for lack of specificity.  
Like Fisher’s claimed ESTs, the chemical group in this 
example asserts a claimed utility (use in “biomedical 
research”) that is broadly applicable to any chemical 
compound.  In order to have specific utility, the claimed 
biomedical research use would need to pertain to a particular 
chemical, physical, or biological property of the compound 
group in order to distinguish it from any other chemical group.  
Thus, under the revised utility test, large chemical groups 
with no claimed biological, physical, or chemical properties 
corresponding to their utility would fail the utility test as they 
would under the current Brenner standard.  Yet, in contrast to 
their failed patentability under the Brenner standard, large 
chemical groups with utility corresponding to specific 
biological, physical, or chemical properties unique to the 
claimed chemical group would be potentially patentable. 
D.  THE REVISED UTILITY TEST SATISFIES THE GOALS OF THE 
PATENT SYSTEM 
1.  Potential Problems with the Revised Test 
The proposed revised utility test would confer more 
patents for research tools than are granted under the current 
test.  This raises concerns about lack of access causing a 
biomedical anticommons, where upstream “clogging” of 
 175. Brenner, 383 U.S. at 535-36. 
 176. See NIH Principles and Guidelines, 64 Fed. Reg. at 72,094. 
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patents for research tools could lead to a decrease in 
downstream innovation.177  When access to important 
research tools is impeded, there is a fear that research will be 
delayed, stopped completely, or conducted without proper 
authorization, thereby threatening to stifle valuable research 
or beget future litigation over patent infringement.178  
Another concern is that a policy promoting more research tool 
patents would unfavorably alter the balance between 
rewarding the inventor and enhancing the public good by 
giving too great a reward to inventors who have put little 
effort into the discovery process179 and “tip[ping] the economic 
balance against drug developm
 177. Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter 
Innovation?  The Anticommons in Biomedical Research, in FOUND. OF 
INTELL. PROP. 177, 178-79 (Robert P. Merges & Jane C. Ginsburg eds., 2004). 
If too many patents are granted for biomedical research tools, the fear is that 
a biomedical anticommons will come into existence. Rebecca Eisenberg and 
Michael Heller assert that a “tragedy of the anticommons” comes into being 
when multiple owners of patents each have the right to exclude others from a 
scarce resource, leaving no one with effective access to the resource. An 
anticommons is essentially a problem of access to research tools, but it is 
more complex than the problem of under-use inherent in the patent system 
in that each upstream patent “allows its owner to set up another tollbooth on 
the road to product development, adding to cost and slowing the pace of 
downstream biomedical innovation.”  Id. 
 178. See Brief for Eli Lilly and Co. as Amicus Curiae Supporting Appellee 
at 4, In re Fisher, 421 F.3d 1365 (Fed. Cir. 2005) (No. 04-1465) (“[S]uch 
claims [for EST patents], if granted, could be used to prevent, threaten to 
prevent, or extract value from everything that might later be discovered 
about genes and proteins associated with genetic sequences.”); Brief for 
Genentech as Amicus Curiae Supporting Appellee at 12, In re Fisher, 421 
F.3d 1365 (Fed. Cir. 2005) (No. 04-1465) (“Patents issued on inventions that 
are yet to be made are harmful to the biotechnology industry and the public, 
because they effectively extinguish commercial interest in developing new 
drugs or diagnostic products based on genomic information.”). 
 179. For example, patents for relatively easily-discovered research tools 
such as ESTs might unjustly reward an inventor who expends little time or 
energy in discovering the EST by conferring a monopoly that extends to 
downstream product development that, in contrast, takes a great expenditure 
of time, money, and effort. 
 180. JAMES D. WATSON, DNA: THE SECRET OF LIFE (2003) (“The large 
royalties demanded by gene-finding monopolies tip the economic balance 
against drug development; cloning a drug target is at most 1 percent of the 
way to an approved drug.”). 
EWING L. In Re Fisher: Denial of Patents for ESTs Signals Deeper Problems in the Utility 
Prong for Patentability. MINN. J.L. SCI. & TECH. 2007;8(2):645-680. 
678 MINN. J. L. SCI. & TECH. [Vol. 8:2 
 
                                                          
 
 
 
2. Solutions to Potential Problems with the Revised Test: 
Narrow Patent Scope and User-Friendly Licensing 
Agreements 
 Narrow patents for research tools and user-friendly 
licensing agreements could limit potential problems associated 
with a proliferation of upstream research tool patents causing 
“clogging” that limits downstream innovation.  Patents for 
research tools should be narrow in scope so that they are 
commensurate with what the invention actually is: a research 
tool.  The patent should not grant rights to downstream 
inventions, such as therapeutic products that treat a disease, 
which will potentially be discovered later.181  A strictly 
enforced specificity prong could provide a means of enforcing 
narrow patents for research tools so that inventors would not 
have broad claims outweighing the amount of work they put 
into the discovery.  For example, inventors who claim ESTs 
with only a general use would not be entitled to a patent, 
while inventors who expend greater effort to identify an 
underlying gene or corresponding protein to distinguish it 
from other ESTs would satisfy the specificity requirement and 
deserve a patent (although it would still be narrow and apply 
only to the EST in its capacity as a research tool). 
Problems of access to patented research tools could also be 
resolved with favorable licensing agreements or research 
exemptions.182  The biomedical research community is a 
collaborative network including public research institutions, 
small private biotechnology companies and large 
pharmaceutical companies, where a strong business 
reputation is vital for the success of its members.  Favorable 
licensing agreements promote strong long-term business 
 181. Using ESTs as an example, a potential patent would not entitle the 
patent holder to claim the entire full-length cDNA or the whole underlying 
gene associated with the EST, but instead only the EST itself in its 
applications as a research tool. 
 182. Several proposals to enable access to patented research tools include 
exclusive licensing arrangements, nonexclusive licensing arrangements, and 
research exemptions.  It is beyond the scope of this Note to discuss these 
options in depth. 
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partnerships and have proved effective in the past for research 
tools, such as PCR.  Upstream patent holders in the 
biomedical research community would have a strong incentive 
to encourage further development of their products because, 
with narrow research tool patents, the ultimate pay-out would 
come from separate patents for the therapeutically useful 
pharmaceutical products that are created downstream.  
Inventors unable to fully develop the downstream products 
associated with their patented research tool would be likely to 
license out use of the research tool (even without a broad 
patent that confers rights to the downstream inventions) 
because they gain a greater economic reward from fees 
associated with licensing than from blocking access to a tool 
they have no intent to develop.  An inventor able and willing 
to develop downstream products could block access to the tool 
without detriment to the public because the downstream 
innovation would still be taking place. 
The tension between rewarding an inventor for her 
contribution to society and contributing to the public good 
with a beneficial invention is a dynamic tension that will 
never be completely resolved, but licensing agreements and 
narrow patent scope may provide a viable means of 
approximating a balance between these two competing 
interests. 
CONCLUSION 
Current controversy exists over the extent to which 
upstream research tools, including ESTs, should be 
patentable.  The fear is that overbroad biomedical research 
patents will cause upstream “clogging” that deters 
downstream invention of vital therapeutic products.  In In re 
Fisher, the court addressed this issue by applying the 
standard of usefulness required for patentable inventions 
under 35 U.S.C. § 101 to ESTs, finding that they were 
unpatentable because they lacked the requisite specific and 
substantial utility and were “only tools to be used along the 
way in the search for a practical utility.”183 
The Fisher analysis reveals that the current test for 
utility fails to address the importance of research tools in 
modern biomedical research and poorly addresses the goals of 
the patent system, thereby necessitating its revision.  A new 
 183. Fisher, 421 F.3d at 1376. 
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test should be adopted, which alters the substantiality prong 
of the utility test in its application to research tools by 
allowing a research use in a laboratory setting to constitute a 
“real world” utility that is substantial.  Such an altered utility 
test, when combined with a narrow patent scope for research 
tools and reasonable licensing schemes, would recognize the 
significance of research tools in modern biomedical research 
by adequately rewarding inventors while promoting the 
“Progress of Science.”184 
 184. U.S. CONST. art. I, § 8, cl. 8. 
